CompletedPhase 1NCT00101153
Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
Studying Acute basophilic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Health Network, Toronto
- Principal Investigator
- Joseph Brandwein, MDPrincess Margaret Hospital, Canada
- Intervention
- cytarabine(drug)
- Enrollment
- 24 enrolled
- Eligibility
- 56 years · All sexes
- Timeline
- 2007
Study locations (2)
- McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
- London Regional Cancer Program at London Health Sciences Centre, London, Ontario, Canada
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00101153 on ClinicalTrials.govOther trials for Acute basophilic leukemia
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT01627041Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid LeukemiaNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGNCT00898456Multidrug Resistance Genes in Patients With Acute Myeloid LeukemiaAlliance for Clinical Trials in Oncology